A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.